(Q48170429)

9 February 2018

title

Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells (English)

1 reference

9 February 2018

1 reference

1 reference

Kochi S

1

1 reference

9 February 2018

Takanaga H

2

1 reference

9 February 2018

Matsuo H

3

1 reference

9 February 2018

Naito M

4

1 reference

9 February 2018

Tsuruo T

5

1 reference

9 February 2018

Sawada Y

6

1 reference

9 February 2018

language of work or name

English

0 references

publication date

1 May 1999

1 reference

9 February 2018

European Journal of Pharmacology

published in

1 reference

9 February 2018

volume

372

1 reference

9 February 2018

issue

3

1 reference

9 February 2018

page(s)

287-295

1 reference

9 February 2018

Hyperkalaemia in cyclosporin-treated renal allograft recipients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Isolation and expression of a complementary DNA that confers multidrug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

A reversible posterior leukoencephalopathy syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Acute reversible central nervous system toxicity associated with low-dose oral cyclosporine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Immunosuppressive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Modulation of energy status and cytotoxicity induced by FK506 and cyclosporin A in a renal epithelial cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Cyclosporin A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Multidrug resistance: molecular biology and clinical relevance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Acute leucoencephalopathy during cyclosporin A therapy in a patient with nephrotic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cord.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Progressive multifocal leukoencephalopathy after orthotopic liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

Lactic dehydrogenase activity in blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900247-2

10.1016/S0014-2999(99)00247-2

7 January 2021

Identifiers

DOI

1 reference

9 February 2018

1 reference

9 February 2018